Real-world evidence use in assessments of cancer drugs by NICE
Open Access
- 10 July 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 36 (4), 388-394
- https://doi.org/10.1017/s0266462320000434
Abstract
To establish how real-world evidence (RWE) has been used to inform single technology appraisals (STAs) of cancer drugs conducted by the National Institute for Health and Care Excellence (NICE). STAs published by NICE from April 2011 to October 2018 that evaluated cancer treatments were reviewed. Information regarding the use of RWE to directly inform the company-submitted cost-effectiveness analysis was extracted and categorized by topic. Summary statistics were used to describe emergent themes, and a narrative summary was provided for key case studies. Materials for a total of 113 relevant STAs were identified and analyzed, of which nearly all (96 percent) included some form of RWE within the company-submitted cost-effectiveness analysis. The most common categories of RWE use concerned the health-related quality of life of patients (71 percent), costs (46 percent), and medical resource utilization (40 percent). While sources of RWE were routinely criticized as part of the appraisal process, we identified only two cases where the use of RWE was overtly rejected; hence, in the majority of cases, RWE was accepted in cancer drug submissions to NICE. RWE has been used extensively in cancer submissions to NICE. Key criticisms of RWE in submissions to NICE are seldom regarding the use of RWE in general; instead, these are typically concerned with specific data sources and the applicability of these to the decision problem. Within an appropriate context, RWE constitutes an extremely valuable source of information to inform decision making; yet the development of best practice guidelines may improve current reporting standards.Keywords
This publication has 17 references indexed in Scilit:
- Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USAFuture Oncology, 2017
- Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell–Depleted Allogeneic Transplantation for Hodgkin LymphomaTransplantation and Cellular Therapy, 2016
- Estimating the cost of caring for people with cancer at the end of life: A modelling studyPalliative Medicine, 2015
- A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin LymphomaLeukemia, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Conditional survival estimates improve over time for patients with advanced melanomaCancer, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Societal preference values for advanced melanoma health states in the United Kingdom and AustraliaBritish Journal of Cancer, 2009
- Costs of palliative care in the community, in hospitals and in hospices in the UKCritical Reviews in Oncology/Hematology, 1999